A Phase III, Multicentre, Randomised, Double-Blind, Controlled Study To Investigate The Efficacy, Safety, And Tolerability Of Two Administrations Of Comp360 In Participants With Treatment-Resistant Depression
Posted Date: Dec 12, 2022
- Investigator: Fabiano Nery
- Specialties:
- Type of Study: Drug
To investigate the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.
Criteria:
Aged =18 Years At Screening, Trd, Defined As Failure To Respond To An Adequate Dose And Duration Of Two, Three, Or Four Different Pharmacological Treatments For The Current Episode,
Keywords:
Depression, Adults With Trd, Psilocybin Therapy
For More Information:
Colette Mueller, M.A.
513 – 558 – 5059
muellec5@ucmail.uc.edu